Vicore Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates
Development of C21 in IPF on track; final Phase 2a AIR data…
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
NEW YORK, December 21, 2023 (GLOBE NEWSWIRE) – IO Biotech (Nasdaq:…
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)…
European Commission revokes all centrally granted generic marketing permissions for dimethyl fumarate (“DMF”), including Dimethyl Fumarate Neuraxpharm
Decision is not due to any public health concerns regarding generic…
4SC AG – Company Update
Planegg-Martinsried, Germany, 20 December 2023 – 4SC AG (4SC,…
Poolbeg Pharma plc – Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI
RSV drug candidates with the highest probability of success prioritised
20…
HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration
Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION…
Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer
Vicore continues to strengthen its leadership in idiopathic…
Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron
• Further strengthening of leadership team following the appointment…
Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury
Mission gains clearance from US FDA for Phase II trial of MTX562…
Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation
AP30663 achieved proof of mechanism with first-in-class SK channel…
Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM
Collaboration with CSEM will speed up identification of suitable…
Biocomposites exceeds revenue expectations and takes a big step forward in its research and development collaboration with Swiss innovator CSEM
New record for sales growth and number of patients supported
…
Versameb Announces Publication in Molecular Therapy – Nucleic Acids Journal Demonstrating the Potential of Engineered IGF-I mRNA as a Regenerative Therapeutic
Basel, Switzerland, 12 December 2023: Versameb AG (“Versameb”),…
Astraveus appoints Dr. Lars Henrik Peeck as Chief Business Development Officer
Paris, France, 12 December 2023 – Astraveus SAS (“Astraveus”…
Poolbeg Pharma – POLB 001 Data Presented at ASH
11 December 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…
STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference
Data demonstrates METTL1 inhibition in vitro at low nanomolar…
Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO Immuno-Oncology Congress 2023
Updated safety and clinical efficacy data presented at leading…
Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia (FTD)
Vesper Bio, backed by Lundbeckfonden BioCapital, initiates…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York